Resverlogix Corp. (TSE:RVX) – Stock analysts at Zacks Investment Research raised their FY2017 earnings per share estimates for shares of Resverlogix Corp. in a research note issued to investors on Wednesday. Zacks Investment Research analyst J. Vandermosten now forecasts that the biotechnology company will post earnings of ($0.38) per share for the year, up from their prior forecast of ($0.51). Zacks Investment Research also issued estimates for Resverlogix Corp.’s Q4 2017 earnings at ($0.06) EPS, FY2018 earnings at ($0.26) EPS and FY2019 earnings at ($0.28) EPS.

TRADEMARK VIOLATION WARNING: “FY2017 EPS Estimates for Resverlogix Corp. Increased by Zacks Investment Research (RVX)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was stolen and republished in violation of US and international copyright laws. The correct version of this news story can be accessed at

Resverlogix Corp. (TSE RVX) opened at 1.39 on Friday. The firm has a 50-day moving average price of $1.94 and a 200-day moving average price of $1.95. Resverlogix Corp. has a one year low of $1.10 and a one year high of $2.47. The firm’s market cap is $146.63 million.

About Resverlogix Corp.

Resverlogix Corp. is a clinical-stage biotechnology company. The Company is a development-stage company, which is engaged in developing apabetalone (RVX-208), a first-in-class small molecule selective Bromodomain and ExtraTerminal domain (BET) inhibitor. Apabetalone is used for the treatment of patients with high-risk cardiovascular disease, (including peripheral arterial disease), diabetes mellitus, chronic kidney disease, Alzheimer’s disease and orphan diseases.

Receive News & Stock Ratings for Resverlogix Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix Corp. and related stocks with our FREE daily email newsletter.